An observational study of bevacizumab combined with FOLFIRI as the first-line treatment in metastatic colorectal cancer

Genomic Medicine, Biomarkers, and Health Sciences

Volumn 4, Issue 4, 2012, Pages 122-127

  Huang, Meng Lin ^a,b   Kan, Jung Yu ^c   Ma, Cheng Jen ^c   Huang, Ching Wen ^c   Chen, Fang Ming ^c,d   Chuang, Chieh Han ^e   Chan, Hon Man ^c,d   Huang, Che Jen ^c,d   Chang, Se Fen ^c   Wen, Yen Hsia ^b   Wang, Jaw Yuan ^c,d,e  

^a ZUOYING ARMED FORCES GENERAL HOSPITAL   (Taiwan)

^b KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^c KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^d KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^e KAOHSIUNG MUNICIPAL HSIAO KANG HOSPITAL   (Taiwan)

Author keywords

Bevacizumab; Efficacy; Irinotecan; Metastatic colorectal cancer; Toxicity

Indexed keywords

BEVACIZUMAB; FLUOROURACIL; FOLINIC ACID; IRINOTECAN;

ADRENAL METASTASIS; ADULT; ADVERSE OUTCOME; AGED; ARTICLE; ASIAN; ASTHENIA; BLOOD TOXICITY; BONE METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CAUCASIAN; COLORECTAL CANCER; CONSTIPATION; CONTINUOUS INFUSION; DIARRHEA; DISEASE SEVERITY; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GASTROINTESTINAL HEMORRHAGE; HUMAN; HYPERTENSION; LIVER METASTASIS; LIVER TOXICITY; LUNG METASTASIS; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; METASTASIS; MUCOSA INFLAMMATION; NAUSEA; OBSERVATIONAL STUDY; OVARY METASTASIS; PERITONEUM METASTASIS; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TREATMENT RESPONSE; VOMITING;

EID: 84878497532     PISSN: 22114254     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.gmbhs.2013.02.001     Document Type: Article

References (21)

1. Cancer registry annual report, Department of Health, Executive Yuan, Taiwan, ROC, 2009.
2. Midgley R., Kerr D. Colorectal cancer. Lancet 1999, 353:391-399.
3. Jaxel C., Kohn K.W., Wani M.C., et al. Structure-activity study of the actions of camptothecin derivatives on mammalian topoisomerase I: evidence for a specific receptor site and a relation to antitumor activity. Cancer Res 1989, 49:1465-1469.
4. Douillard J.Y., Cunningham D., Roth A.D., et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 2000, 355:1041-1047.
5. Saltz L.B., Cox J.V., Blanke C., et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 2000, 343:905-914.
6. Kohne C.H., van Cutsem E., Wils J., et al. Phase III study of weekly high-dose infusional fluorouracil plus folinic acid with or without irinotecan in patients with metastatic colorectal cancer: European Organisation for Research and Treatment of Cancer Gastrointestinal Group study 40986. J Clin Oncol 2005, 23:4856-4865.
7. Presta L.G., Chen H., O'Connor S.J., et al. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 1997, 57:4593-4599.
8. Fuchs C.S., Marshall J., Mitchell E., et al. Randomized controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C study. J Clin Oncol 2007, 25:4779-4786.
9. Hurwitz H., Fehrenbacher L., Novotny W., et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004, 350:2335-2342.
10. Therasse P., Arbuck S.G., Eisenhauer E.A., et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000, 92:205-216.
11. Rosati G., Cordio S., Aprile G., et al. Discontinuation of bevacizumab and FOLFIRI administered up to a maximum of 12 cycles as first-line therapy for metastatic colorectal cancer: a retrospective Italian study. Invest New Drugs 2012, 30:1978-1983.
12. Stintzing S., Fischer von Weikersthal L., Decker T., et al. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer-subgroup analysis of patients with KRAS: mutated tumours in the randomised German AIO study KRK-0306. Ann Oncol 2012, 23:1693-1699.
13. Sobrero A., Ackland S., Clarke S., et al. Phase IV study of bevacizumab in combination with infusional fluorouracil, leucovorin and irinotecan (FOLFIRI) in first-line metastatic colorectal cancer. Oncology 2009, 77:113-119.
14. Souglakos J., Ziras N., Kakolyris S., et al. Randomised phase-II trial of CAPIRI (capecitabine, irinotecan) plus bevacizumab vs FOLFIRI (folinic acid, 5-fluorouracil, irinotecan) plus bevacizumab as first-line treatment of patients with unresectable/metastatic colorectal cancer (mCRC). Br J Cancer 2012, 106:453-459.
15. López R., Salgado M., Reboredo M., et al. A retrospective observational study on the safety and efficacy of first-line treatment with bevacizumab combined with FOLFIRI in metastatic colorectal cancer. Br J Cancer 2010, 103:1536-1541.
16. Ocvirk J., Rebersek M., Boc M. Bevacizumab in first-line therapy of metastatic colorectal cancer: a retrospective comparison of FOLFIRI and XELIRI. Anticancer Res 2011, 31:1777-1782.
17. Van Cutsem E., Rivera F., Berry S., et al. Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study. Ann Oncol 2009, 20:1842-1847.
18. Nishi T., Hamamoto Y., Warita E., et al. Retrospective analysis of the international standard-dose FOLFIRI (plus bevacizumab) regimen in Japanese patients with unresectable advanced or recurrent colorectal carcinoma. Int J Clin Oncol 2011, 16:488-493.
19. Yildiz R., Benekli M., Ozkan M., et al. Bevacizumab every 4 weeks is as effective as every 2 weeks in combination with biweekly FOLFIRI in metastatic colorectal cancer. J Cancer Res Clin Oncol 2012, 138:1845-1852.
20. Odabas H., Ozdemir N., Abali H., et al. First-line therapy for metastatic colorectal carcinoma: modified FOLFOX4 or FOLFIRI-bevacizumab. J BUON 2011, 16:247-252.
21. Chen C.F., Yeh Y.S., Chen F.M., et al. Efficacy and safety of two different regimens of irinotecan for metastatic colorectal cancer: experience in a southern Taiwan medical center. J Soc Colon Rectal Surgeon (Taiwan) 2008, 19:97-107.